Impact of long-acting therapies on the global HIV epidemic.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
26
3
2022
Statut:
ppublish
Résumé
Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current daily-based oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.
Identifiants
pubmed: 34848580
doi: 10.1097/QAD.0000000000003102
pii: 00002030-202112152-00005
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S137-S143Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with human immunodeficiency virus on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities . Clin Infect Dis 2018; 66:1487–1491.
UNAIDS Global HIV Update 2020 – Seizing the moment: tackling entrenched inequalities to end epidemics. 2020.
Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review . AIDS Care 2015; 27:805–816.
Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis . PLoS Med 2016; 13:e1002183.
Flexner C. Antiretroviral implants for treatment and prevention of HIV infection . Curr Opin HIV AIDS 2018; 13:374–380.
Boyd MA, Cooper DA. Long-acting injectable ART: next revolution in HIV? . Lancet 2017; 390:1468–1470.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard P-M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection . New Engl J Med 2020; 382:1124–1135.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression . New Engl J Med 2020; 382:1112–1123.
Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, et al. Creation of a long-acting nanoformulated dolutegravir . Nat Commun 2018; 9:443.
Psaros C, Remmert JE, Bangsberg DR, Safren SA, Smit JA. Adherence to HIV care after pregnancy among women in sub-Saharan Africa: falling off the cliff of the treatment cascade . Curr HIV/AIDS Rep 2015; 12:1–5.
Benning L, Mantsios A, Kerrigan D, Coleman JS, Golub E, Blackstock O, et al. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy . BMC Women's health 2020; 20:152.
Goedel WC, Nunn AS, Chan PA, Duncan DT, Biello KB, Safren SA, Marshall BDL. A shot at equity? Addressing disparities among Black MSM in the coming era of long-acting injectable preexposure prophylaxis . AIDS 2019; 33:2110–2112.
Philbin MM, Parish CL, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, et al. Multisite study of women living with HIV's perceived barriers to, and interest in, long-acting injectable antiretroviral therapy . J Acquir Immune Defic Syndr 19992020; 84:263–270.
Fields EL, Hussen SA, Malebranche DJ. Mind the gap: HIV prevention among young black men who have sex with men . Curr HIV/AIDS Rep 2020; 17:632–642.
Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, et al. Multilevel considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of healthcare providers participating in phase 3 trials . BMC Health Serv Res 2021; 21:255.
Parker B, Ward T, Hayward O, Jacob I, Arthurs E, Becker D, et al. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study . PloS One 2021; 16:e0245955.
Tsui AO, Brown W, Li Q. Contraceptive practice in sub-Saharan Africa . Popul Dev Rev 2017; 43: (Suppl 1): 166–191.
Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, et al. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection . HIV Clin Trials 2018; 19:85–93.
Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Preexposure prophylaxis 2.0: new drugs and technologies in the pipeline . Lancet HIV 2019; 6:e788–e799.
Health NIo. Long-acting injectable form of HIV prevention outperforms daily pill in NIH study. 2020.
Agency EM. Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden. 2020.
Collins S. HIV pipeline 2020: new drugs in development – March 2020. 2020.
Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, et al. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities . Lancet HIV 2019; 6:e552–e558.
Jefferys R. HIV vaccines, passive immunization, and antibody gene transfer pipeline. 2020. 2020. https://www.treatmentactiongroup.org/wpcontent/uploads/2020/07/pipeline_HIV_vaccine_2020.pdf .
Jansssen. Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV. 2021.
Agency EM. First long-acting injectable antiretroviral therapy for HIV recommended for approval. 2020.
Healthcare V. ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment. 2021.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, noninferiority study . Lancet 2021; 396:1994–2005.
Havlir D, Gandhi M. Implementation challenges for long-acting antivirals as treatment . Current opinion in HIV and AIDS 2015; 10:282–289.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting injectable Cabotegravir + Rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR Trials . J Acquir Immune Defic Syndr 19992020; 85:498–506.
Carnes SK, Sheehan JH, Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity . Curr Opin HIV AIDS 2018; 13:359–365.
Molina J. Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks. HIV Glasgow 2020, abstract O415. 2020.
Markham A. Ibalizumab: first global approval . Drugs 2018; 78:781–785.
Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research . Expert Opin Drug Deliv 2020; 17:1227–1238.
Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain . PloS One 2018; 13:e0190487.
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of Cabotegravir and Rilpivirine over 48 weeks . AIDS Behav 2020; 24:3533–3544.
Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients . Nanomedicine (Lond) 2013; 8:1807–1813.
Kerrigan D, Sanchez Karver T, Muraleetharan O, Savage V, Mbwambo J, Donastorg Y, et al. A dream come true’: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania . PloS One 2020; 15:e0234666.
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks . AIDS Behav 2020; 24:3533–3544.
Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression . N Engl J Med 2020; 382:1112–1123.
Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076) . J Int AIDS Soc 2019; 22:e25408.
WHO Think-tank Meeting on Optimizing AntiRetroviral Therapy: meeting report, 12 March 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/338735/9789240016378-eng.pdf?sequence=1&isAllowed=y .
Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a Mathematical Modeling Study . J Infect Dis 2020; 224:1179–1186.
Hill A. Review of long-acting injectable candidates for HIV treatment and prevention. 2018.
Dorward J, Msimango L, Gibbs A, Shozi H, Tonkin-Crine S, Hayward G, et al. Understanding how community antiretroviral delivery influences engagement in HIV care: a qualitative assessment of the Centralised Chronic Medication Dispensing and Distribution programme in South Africa . BMJ Open 2020; 10:e035412.
Fox MP, Pascoe S, Huber AN, Murphy J, Phokojoe M, Gorgens M, et al. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa . PLoS Med 2019; 16:e1002874.
Lerma K, Goldthwaite LM. Injectable contraception: emerging evidence on subcutaneous self-administration . Curr Opin Obstet Gynecol 2019; 31:464–470.
Flexner C, Thomas DL, Swindells S. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis . Curr Opin HIV AIDS 2019; 14:13–20.
Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, et al. Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection . Antimicrob Agents Chemother 2019; 63:e00007-19.
Bakshi RP, Tatham LM, Savage AC, Tripathi AK, Mlambo G, Ippolito MM, et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis . Nat Commun 2018; 9:315.
Macintyre F, Ramachandruni H, Burrows JN, Holm R, Thomas A, Möhrle JJ, et al. Injectable antimalarials revisited: discovery and development of new agents to protect against malaria . Malaria J 2018; 17:402.
Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety . Malar J 2017; 16:161.
Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study . Lancet Infect Dis 2020; 20:498–508.
Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV . Lancet HIV 2020; 7:e443–e448.
Thomas DL. Global elimination of chronic hepatitis . New Engl J Med 2019; 380:2041–2050.
Culhane J, Sharma M, Wilson K, Roberts DA, Mugo C, Wamalwa D, et al. Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya . EClinicalMedicine 2020; 25:100453.
Hobson JJ, Al-khouja A, Curley P, Meyers D, Flexner C, Siccardi M, et al. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies . Nat Commun 2019; 10:1413.
Kulkarni TA, Bade AN, Sillman B, Shetty BLD, Wojtkiewicz MS, Gautam N, et al. A year-long extended release nanoformulated cabotegravir prodrug . Nat Mater 2020; 19:910–920.
Hu X, Lin X, Gu Y, Liu Z, Tang Y, Zhang Y, et al. Biocompatible riboflavin laurate long-acting injectable nanosuspensions allowing sterile filtration . Drug Deliv 2014; 21:351–361.
Kalicharan RW, Oussoren C, Schot P, de Rijk E, Vromans H. The contribution of the in-vivo fate of an oil depot to drug absorption . Int J Pharm 2017; 528:595–601.
IAVI. IAVI and Scripps Research Join Efforts with NIH to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products. 2020.
Bhugra D. The global prevalence of schizophrenia . PLoS medicine 2005; 2:e151.
Gopal S, Xu H, McQuarrie K, Savitz A, Nuamah I, Woodruff K, Mathews M. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies . NPJ Schizophr 2017; 3:23.
Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia . Schizophr Res 2018; 197:274–280.
Phillips AN, Bansi-Matharu L, Cambiano V, Ehrenkranz P, Serenata C, Venter F, et al. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis . Lancet Glob Health 2021; 9:e620–e627.
Di Giorgio L, Mvundura M, Tumusiime J, Namagembe A, Ba A, Belemsaga-Yugbare D, et al. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal . Contraception 2018; 98:389–395.